Lifebit unlocks the potential of diverse data to accelerate pharmaceutical R&D
The company says this achievement signifies a major advancement in research and development capabilities within the pharmaceutical industry, driven by the federated data partnerships forged by Lifebit.
In an era where traditional drug development processes are characterized by sluggishness, exorbitant costs, and inefficiency, Lifebit says its milestone is a beacon of hope.
The company says that since the 1950s, research and development efficiency have plummeted, with an alarming 80-fold drop in drug productivity and the cost to develop new drugs doubling every nine years. The key to unlocking the future of drug development, it says, lies in secure access to population-level standardized clinical and multi-omic data.
Lifebit's catalog comprises comprehensive multi-omic and health datasets, encompassing more than 200 health conditions. Significantly, these datasets cover disease areas that pose the most significant threats to human health, including cancer, cardiovascular diseases, respiratory ailments, neurological disorders, diabetes, and rare diseases.
Data driving drug development productivity
In a landscape where data holds court as the new driver of productivity for drug development, Lifebit says its expansive and diverse data network presents unparalleled opportunities for research and development. It facilitates expedited identification of drug targets and streamlines the process of conducting clinical trials.
This data milestone coincides with the recent launch of Lifebit's Platform 2.0. It is meticulously designed, Lifebit says, to maximize research discoveries while prioritizing data privacy and security.
The platform, it says represents ‘a paradigm shift in precision medicine research’, offering advanced federated analytics, automated AI-powered data standardization, seamless collaboration across disparate datasets, no-code cohort building, and data-driven drug discovery capabilities.
Coupled with access to diverse data from over 100 million patients, the company says its platform empowers researchers worldwide to securely connect and analyze invaluable real-world, clinical, and genomic data in compliance with regulatory standards.
Data for R&D
Lifebit collaborates closely with leading healthcare providers, non-profits, research institutions, and population genomics initiatives across five continents to facilitate the safe and secure accessibility of their data for research and development endeavors.
Maria Dunford, CEO of Lifebit, said: "Access to high volumes of diverse data is paramount for understanding diseases and discovering new drugs and treatments, yet it remains a significant barrier in the pharmaceutical industry.
“Our data catalog, comprising information from over 100 million patients, represents the deepest and most diverse clinico-genomics data resource globally, and we are thrilled to offer this to the industry. It has the potential to be transformative for our pharma partners, advancing precision medicine and generating new discoveries that save lives. We take immense pride in supporting our federated data partners in unlocking the potential of their data while safeguarding the privacy of patient participants.”
In essence, Lifebit believes its groundbreaking achievement marks a significant leap forward in the quest for innovative solutions in pharmaceutical research and development, propelling the industry toward a future characterized by efficiency, efficacy, and patient-centricity.
